Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

Stopped early · Not applicable

Conditions studied: Diabetes, Pre-diabetes, Obesity

In brief

The investigators know that metformin works at the level of the cells in the body by acting on a protein called Cyclic amine monophosphate- Response Binding Elements (CREB) binding protein or Constitutive Reverter of eIF2α Phosphorylation (CREP) Binding Protein (CBP). What the investigators do not know is how this process is affected when the dose of the metformin is increased or changed. Currently the same doses of metformin are often used in both children and adults, but it is possible that the dose of metformin should be based on age and weight. Understanding how CBP works could potentially help us to tailor metformin treatment individually for patients based on their age, weight and CBP response.

Key facts

Study ID
NCT01876992
Run by
Johns Hopkins University
People needed
10
Starts
2012-01-01
Expected to finish
2015-06-01
Last updated by the study team
2017-09-26

Who can join

Age: 10 and older, up to 79. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.